These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients. Hillebrand U; Suwelack BM; Loley K; Lang D; Reuter S; Amler S; Pavenstädt H; Hausberg M; Büssemaker E Transpl Int; 2009 Nov; 22(11):1073-80. PubMed ID: 19624495 [TBL] [Abstract][Full Text] [Related]
3. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug. Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208 [TBL] [Abstract][Full Text] [Related]
4. Current status of antihypertensive prescription and associated blood pressure control in Japan. Mori H; Ukai H; Yamamoto H; Saitou S; Hirao K; Yamauchi M; Umemura S Hypertens Res; 2006 Mar; 29(3):143-51. PubMed ID: 16755149 [TBL] [Abstract][Full Text] [Related]
5. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Weir MR Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185 [TBL] [Abstract][Full Text] [Related]
6. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs. Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973 [TBL] [Abstract][Full Text] [Related]
7. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Verdecchia P; Angeli F; Cavallini C; Gattobigio R; Gentile G; Staessen JA; Reboldi G Eur Heart J; 2009 Mar; 30(6):679-88. PubMed ID: 19168534 [TBL] [Abstract][Full Text] [Related]
8. Blood pressure and serum potassium levels in hypertensive patients receiving or not receiving antihypertensive treatment. Pikilidou MI; Lasaridis AN; Sarafidis PA; Tziolas IM; Zebekakis PE; Dombros NV; Giannoulis E Clin Exp Hypertens; 2007 Nov; 29(8):563-73. PubMed ID: 18058481 [TBL] [Abstract][Full Text] [Related]
9. [Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment]. Qiu YG; Yao XY; Tao QM; Zheng P; Chen JZ; Zhu JH; Zhang FR; Zheng LR; Zhao LL Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug; 25(8):710-4. PubMed ID: 15555399 [TBL] [Abstract][Full Text] [Related]
10. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. Ruggenenti P; Perna A; Ganeva M; Ene-Iordache B; Remuzzi G; J Am Soc Nephrol; 2006 Dec; 17(12):3472-81. PubMed ID: 17082240 [TBL] [Abstract][Full Text] [Related]
11. Antihypertensive medication changes and blood pressure goal achievement in a managed care population. Engel-Nitz NM; Darkow T; Lau H J Hum Hypertens; 2010 Oct; 24(10):659-68. PubMed ID: 20107489 [TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415 [TBL] [Abstract][Full Text] [Related]